FindTrial
Sign In

CHANGES IN NERVE FUNCTION AND DISABILITY IN LEPROSY PATIENTS WHILE ON TREATMENT

A PROSPECTIVE, OBSERVATIONAL STUDY TO ASSESS THE CHANGES IN NERVE FUNCTION IMPAIRMENT(NFI) AND DISABILITY STATUS IN LEPROSY PATIENTS ON ANTI-LEPROSY TREATMENT

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/02/039908
Enrollment
40
Registered
2022-02-01
Start date
Unknown
Completion date
Unknown
Last updated
2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A309- Leprosy, unspecified

Interventions

Intervention1: NIL: NIL

Sponsors

PGIMER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients who give valid consent/assent. 2. Patients of either gender with age 14 and above. 3. All patients being started on anti-leprosy treatment: multidrug therapy (MDT) or alternative therapy in cases with drug resistanceas per WHO guidelines69

Exclusion criteria

Exclusion criteria: 1. Patients who are not willing to provide consent for the study. 2. Patient of age 3. Patients at risk of a neuropathy other than leprosy, i.e. diabetes, alcoholism, risk group for HIV infection, patients with a family history of hereditary neuropathy.

Design outcomes

Primary

MeasureTime frame
To assess nerve function impairment(NFI) and disability status in leprosy patients on anti-leprosy treatment(ALT)Timepoint: Will be done as 3 monthly assessment till 1 year study period—

Secondary

MeasureTime frame
To study the predictors of changes (improvement or worsening) in nerve function impairment(NFI)Timepoint: 1 year—

Countries

India

Contacts

Public ContactDr Apoorva Sharma

PGIMER Chandigarh

sundogra@hotmail.com9855005941

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026